Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancerologie Cutanee, GCC).

ABSTRACT:

Background

The long-term effectiveness of immune checkpoint inhibitor (ICI) rechallenge for progressive or recurrent advanced melanoma following previous disease control induced by ICI has not been thoroughly described in the literature.

Patients and methods

In this retrospective multicenter national real-life study, we enrolled patients who had been rechallenged with an ICI after achieving disease control with a first course of ICI, which was subsequently interrupted. The primary objective was to evaluate tumor response, while the secondary objectives included assessing the safety profile, identifying factors associated with tumor response, and evaluating survival outcomes.

Results

A total of 85 patients from 12 centers were included in the study. These patients had

SUBMITTER: Nardin C 

PROVIDER: S-EPMC10377277 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature